Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

ClinicalTrials.gov ID: NCT05283226

Public ClinicalTrials.gov record NCT05283226. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.

Study identification

NCT ID: NCT05283226
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: NATCO Pharma Ltd.; Industry
Enrollment: 21 participants

Conditions and interventions

Conditions

Interventions

NRC-2694-A Drug
Paclitaxel Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 29, 2022
Primary completion: Dec 29, 2026
Completion: Jun 29, 2027
Last update posted: Jan 22, 2026

2022 – 2027

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Providence Medical Foundation -Fullerton	Fullerton	California	92835	Completed
Los Angeles Hematology Oncology Medical Group	Los Angeles	California	90017	Completed
Lynn Cancer Center	Boca Raton	Florida	33486	Completed
Miami Cancer Center	Miami	Florida	33176	Completed
Norton Cancer Institute - Downtown	Louisville	Kentucky	40202	Completed
University of Maryland Greenebaum Cancer Center	Baltimore	Maryland	21201-1544	Completed
Washington University - Siteman Cancer Center	St Louis	Missouri	63110	Completed
Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire	03756-1000	Completed
Salib Oncology	Easton	Pennsylvania	18045	Completed
University of Wisconsin Carbone Cancer Center	Madison	Wisconsin	53792	Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05283226, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 22, 2026 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05283226 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →